406683-19-0

Basic information

• Product Name: Hydrazinecarboxylic acid, 2-(2-propynyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Hydrazinecarboxylic acid, 2-(2-propynyl)-, 1,1-dimethylethyl ester (9CI)
• CAS NO: 406683-19-0
• Molecular Formula: C₈H₁₄N₂O₂
• Molecular Weight: 170.20896
• Product Categories: N-BOC
• Mol File: 406683-19-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Hydrazinecarboxylic acid, 2-(2-propynyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Hydrazinecarboxylic acid, 2-(2-propynyl)-, 1,1-dimethylethyl ester (9CI)(406683-19-0)
• EPA Substance Registry System: Hydrazinecarboxylic acid, 2-(2-propynyl)-, 1,1-dimethylethyl ester (9CI)(406683-19-0)

Safety Data

• Hazardous Substances Data: 406683-19-0(Hazardous Substances Data)

Upstream product

• 870-46-2 t-butoxycarbonylhydrazine 
• 106-96-7 propargyl bromide 

Relevant articles and documents

Diversity-Oriented A3-Macrocyclization for Studying Influences of Ring-Size and Shape of Cyclic Peptides: CD36 Receptor Modulators

Cyclic peptide diversity has been broadened by elaborating the A3-macrocyclization to include various di-amino carboxylate components with different N?-amine substituents. Triple-bond reduction provided new cyclic peptide macrocycles with Z-olefin and completely saturated structures. Moreover, cyclic azasulfurylpeptides were prepared by exchanging the propargylglycine (Pra) component for an amino sulfamide surrogate. Examination of such diversity-oriented methods on potent cyclic azapeptide modulators of the cluster of differentiation 36 receptor (CD36) identified the importance of the triple bond as well as the N?-allyl lysine and azaPra residues for high CD36 binding affinity. Cyclic azapeptides which engaged CD36 effectively reduced pro-inflammatory nitric oxide and downstream cytokine and chemokine production in macrophages stimulated with a Toll-like receptor-2 agonist. Studying the triple bond and amine components in the multiple-component A3-macrocyclization has given a diverse array of macrocycles and pertinent information to guide the development of ideal CD36 modulators with biomedical potential for curbing macrophage-driven inflammation.

NOVEL CYCLIC PEPTIDES AND USES THEREOF

Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of CD36-related dise

Combinatorial aid for underprivileged scaffolds: Solution and solid-phase strategies for a rapid and efficient access to novel aza-diketopiperazines (aza-DKP)

An efficient solution-phase synthesis of aza-diketopiperazines (aza-DKP, triazinediones) is reported. A structurally diverse collection of c-[aza-alkylGly-Pro] derivatives and yet unreported 2,4,5-trisubstituted-1,2,4- triazine-3,6-diones has been synthesized starting from Fmoc-l-Pro-OH and various Fmoc-l-amino acids. To extend the practical value of this class of dipeptidomimetics, a general solid-phase synthesis approach amenable to library production was developed on both Wang-PS and HMBA-PS resins. The final acidic treatment of the resins in TFA/water mixture at room temperature enabled the rapid and quantitative cyclization/release highly pure triazinediones. The conformational preferences and the spatial organization of the three substituents of a representative 2,4,5-trisubstituted-1,2,4-triazine-3,6-dione were investigated by X-ray diffraction and 1H NMR spectroscopy.

Pyridazinoquinolinetriones as NMDA glycine-site antagonists with oral antinociceptive activity in a model of neuropathic pain

A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyi)alkyl]-pyridazino[4,5-b] quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.